An increased risk of a hard or ‘no deal Brexit?

24 Dec 2018

A ‘no deal’ Brexit will change and burden how all industries that move materials and goods across borders, including the pharmaceutical and medical device sectors, do business.

Pharmaceutical companies still do not know how they will be affected by Brexit after Prime Minister Theresa May decided to postpone a vote on her deal with the European Union (EU).

An increased risk of a hard or ‘no deal Brexit?

The delay was announced just a day before Parliament was due to decide whether to accept the draft framework agreement negotiated with the EU over the past 2 years. The deal as it currently stands faces strong opposition, and most observers had predicted it would not pass.

The vote, now set to take place in mid-January, would provide some clarity on how the development, manufacture and sale of pharmaceuticals and medical devices would be regulated after Brexit.

Whether the agreement can be renegotiated remains to be seen so at present there is an increased risk of a hard or ‘no deal Brexit where the UK potentially withdraws from the EU without a trading agreement.

A ‘no deal’ Brexit, if it happens – the European Court of Justice (ECJ) confirmed the UK can halt the Article 50 process unilaterally before 29 March – is predicted by many experts to risk huge social and economic impact.

It will also change and burden how all industries that move materials and goods across borders, including the pharmaceutical and medical device sectors, do business.

Supply chain disruption

Medicine supply chains between the UK and EU will be affected according to the Association for British Pharmaceutical Industries’ (ABPI) chief exective, Mike Thompson.

Writing in response to a government update he said: “Pharmaceutical companies continue to do everything in their power to make sure that patients get access to medicines whatever the Brexit scenario. This includes duplicating processes, changing supply routes and stockpiling medicines in line with the Government’s guidance. However, we have been clear that there are things which are out of our control.

“This update on potential border delays for 6 months in a ‘no deal’ scenario is stark. Stockpiling more medicines is not the solution to this problem,” Thompson continued, adding, “We welcome the Secretary of State’s intention to prioritise the flow of medicines and vaccines. But with just 16 weeks until the UK leaves the EU, we need the detail.”

He urged the Government to take immediate action to open up alternative supply routes between the UK and Europe and tell companies so they can make plans.

Third country controls

The UK BioIndustry Association raised similar concerns, noting the government has provided little information on actions it is planning beyond ensuring there is sufficient roll-on, roll-off freight capacity and that medicines will be prioritised on alternative routes.

It wrote: “A ‘no deal’ Brexit would mean the biggest dis-integration of the complex regulated medicines market across Europe in terms of regulation, cross border movement of goods, comparative pricing and intellectual property. The organisation also pointed out that many key parts of the UK’s future trading relationship will be decided in Brussels.

“The European Commission has made it clear that, in the event of a ‘no deal’ scenario, it will impose full third country controls on people and goods entering the EU from the UK. Whether this happens or not is in their hands, not ours,” it said.

Regulatory uncertainty

Regulations covering the development, manufacture and assessment of pharmaceutical products will also change under a ‘no-deal’ Brexit. It is not clear which EU rules will be written into UK law. For example, new on-pack safety feature regulations are likely to apply, but parts of the EU Clinical Trial Regulation (CTR) may not, according to the European Commission

Neither is it certain how the Medicines and Healthcare products Regulatory Agency (MHRA) will interact with the European Medicines Agency (EMA) with respect to, among other activities, manufacturing facility inspections.

Previously, the UK regulator has been very visible in Europe, ensuring that EU regulations have been pragmatic, favourable to innovation and forward-looking while protecting patient interests.

Other key questions remain regarding pharmacovigilance activities – which must take place in an EU member state or EEA territory – as well as batch release and certification.

RAPS is closely monitoring this period of uncertainty and transition and is committed to informing regulatory professionals with the latest news and insights as they develop.

Read More

Related tags

Top Stories Market News

Related news

'Tamper-evident' benefits are evident

'Tamper-evident' benefits are evident

28 Feb 2019

2019 will mark Uniplast's debut at this year's edition of CPhI Worlwide in Frankfurt, where it will showcase its expertise in plastic packaging.

Read more 
All Recipharm facilities ready for EU serialisation, regardless of Brexit

All Recipharm facilities ready for EU serialisation, regardless of Brexit

15 Feb 2019

The CDMO invested EUR 35 million into its operations and launched a 3-year programme to provide a compliant serialisation solution for its customers.

Read more 
Brexit - the EU FMD's painful problem

Brexit - the EU FMD's painful problem

7 Feb 2019

Teething problems are no stranger to the implementation of new regulations, but with the EU FMD, Brexit came like a set of wisdom teeth – late, painful and problematic.

Read more 
Pharmapack report predicts diversification of innovation leading to a rise in licensing and partnering

Pharmapack report predicts diversification of innovation leading to a rise in licensing and partnering

27 Jan 2019

New report highlights Germany, France and Switzerland as tier-one nations for ‘drug delivery innovation’, and warns the challenge will be to scale-up and approve promising prototypes.

Read more 
New API screening program strengthens Particle Sciences' nanomilling offering

New API screening program strengthens Particle Sciences' nanomilling offering

22 Jan 2019

Advanced formulation techniques such as nanomilling may provide an excellent route to improved bioavailability and enhanced therapeutic effect.

Read more 
Univercells introduces breakthrough vaccine manufacturing platform

Univercells introduces breakthrough vaccine manufacturing platform

13 Jan 2019

The automated NevoLine bioproduction system that facilitates safer, faster and closed bioprocessing in a much smaller footprint.

Read more 
BMS and Celgene merge to create premier innovative biopharma company

BMS and Celgene merge to create premier innovative biopharma company

3 Jan 2019

Significantly expands Phase III assets with six expected near-term product launches, representing greater than $15 billion in revenue potential.

Read more 
One month on: medical cannabis is still taboo despite change in law

One month on: medical cannabis is still taboo despite change in law

11 Dec 2018

Restrictive guidelines have led many to buy CBD products online, leading to a boom in production with many products going to market without sufficient quality control.

Read more 
EU FMD - time is running out!

EU FMD - time is running out!

13 Nov 2018

Companies that have left it too late to implement their own solution will have to rely on support from providers, whose resources are already in high demand as the deadline approaches.

Read more 
Proprietary nasal delivery formulation of diazepam reaches NDA

Proprietary nasal delivery formulation of diazepam reaches NDA

7 Nov 2018

The absolute bioavailability of the Valtoco intranasal formulation was 96% of intravenous diazepam in a Phase I cross-over trial.

Read more